Difference between revisions of "Part:BBa K3846351:Design"
Crisprcaspr (Talk | contribs) |
|||
Line 1: | Line 1: | ||
− | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K3846351 short</partinfo> | <partinfo>BBa_K3846351 short</partinfo> | ||
Line 7: | Line 6: | ||
===Design Notes=== | ===Design Notes=== | ||
− | |||
+ | based on studies conducted by J. Keasling <i> et al.</i>. | ||
+ | ===Source=== | ||
− | + | Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Metab Eng. 2009 Jan;11(1):13-9. doi: 10.1016/j.ymben.2008.07.007. Epub 2008 Aug 12. 10.1016/j.ymben.2008.07.007 | |
− | + | [https://www.addgene.org/100167/] | |
+ | [https://www.addgene.org/100169/] | ||
===References=== | ===References=== |
Latest revision as of 10:55, 20 October 2021
MBIS pathway
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
based on studies conducted by J. Keasling et al..
Source
Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Metab Eng. 2009 Jan;11(1):13-9. doi: 10.1016/j.ymben.2008.07.007. Epub 2008 Aug 12. 10.1016/j.ymben.2008.07.007